RIGL
RIGEL PHARMACEUTICALS INC
Next earnings Aug 3, 2026 · consensus $0.96 EPS, $70.0M rev
Last earnings -4.9% on 2026-05-05
$38.69
▲ +4.60%$38.69▲ +105.31%
over 1Y
L $18.42EODHDH $50.96
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.6%
1W+8.3%
1M+31.2%
3M+49.9%
YTD-7.5%
1Y+105.3%
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Revenue grew 64.1% YoY.
Revenue (FY2025) $294M · FY2025
The read
Quality fundamentals and an attractive price line up (~1813% below fair value) — the rarer case where both the business and the entry look good.
RIGEL PHARMACEUTICALS INC shows $294M in FY2025 revenue (+64.1% YoY), a 124.7% net margin, and 93.8% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $149M | $120M | $117M | $179M | $294M |
| Gross profit | — | — | — | — | — |
| Operating income | -$12.5M | -$55.5M | -$20.5M | $24.2M | $125M |
| Net income | -$17.9M | -$58.6M | -$25.1M | $17.5M | $367M |
| Diluted EPS | -$0.11 | -$3.44 | -$1.44 | $0.99 | $19.48 |
| Net margin | -12.0% | -48.7% | -21.5% | 9.8% | 124.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$727M
EV / EBITDA5.7
EV / Sales2.5
EV / FCF9.7
P / FCF9.5
PEG (trailing)0.00
Earnings yield51.4%
FCF yield10.5%
Quality & risk
ROIC (est.)22.3%
Free cash flow$75.2M
Total debt$52.5M
Net cash-$11.9M
Altman Z-Score2.43 grey
Piotroski F-Score5/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+3.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-04-21). Worth a closer look.
Recent filings
all on EDGAR ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗144Filing2026-06-22open ↗8-KPeriod ending 2026-06-112026-06-17open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗
Frequently asked
- Is RIGEL PHARMACEUTICALS INC (RIGL) a buy?
- RIGL currently carries a Buy rating with 5/5 conviction, derived from its latest SEC filings. Revenue grew 64.1% YoY.
- What is RIGL's fair value?
- A Modified-Graham model based on RIGL's SEC fundamentals estimates a fair value of about $740.24. It is an estimate from reported earnings, not a price target.
- Is RIGL overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, RIGL currently appears undervalued relative to its SEC-grounded earnings power.
- What is RIGEL PHARMACEUTICALS INC's quality score?
- RIGL scores 89.15686274509802/100 (grade A) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001034842, latest 10-Q filed 2026-05-05) · EODHD · as of 6/26/2026, 7:07:38 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.